These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 2017655)

  • 1. Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice.
    Eugui EM; Mirkovich A; Allison AC
    Scand J Immunol; 1991 Feb; 33(2):175-83. PubMed ID: 2017655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolic acid directly protects podocytes by preserving the actin cytoskeleton and increasing cell survival.
    Abo Zed SED; Hackl A; Bohl K; Ebert L; Kieckhöfer E; Müller C; Becker K; Fink G; Nüsken KD; Nüsken E; Müller RU; Schermer B; Weber LT
    Sci Rep; 2023 Mar; 13(1):4281. PubMed ID: 36922538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-Invasive Monitoring for Rejection in Kidney Transplant Recipients After SARS-CoV-2 mRNA Vaccination.
    Al Jurdi A; Gassen RB; Borges TJ; Solhjou Z; Hullekes FE; Lape IT; Efe O; Alghamdi A; Patel P; Choi JY; Mohammed MT; Bohan B; Pattanayak V; Rosales I; Cravedi P; Kotton CN; Azzi JR; Riella LV
    Front Immunol; 2022; 13():838985. PubMed ID: 35281011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of broad anti-coronavirus chemical agents for repurposing against SARS-CoV-2 and variants of concern.
    Murer L; Volle R; Andriasyan V; Petkidis A; Gomez-Gonzalez A; Yang L; Meili N; Suomalainen M; Bauer M; Policarpo Sequeira D; Olszewski D; Georgi F; Kuttler F; Turcatti G; Greber UF
    Curr Res Virol Sci; 2022; 3():100019. PubMed ID: 35072124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alteration of the gut microbiome in mycophenolate-induced enteropathy: impacts on the profile of short-chain fatty acids in a mouse model.
    Jardou M; Provost Q; Brossier C; Pinault É; Sauvage FL; Lawson R
    BMC Pharmacol Toxicol; 2021 Oct; 22(1):66. PubMed ID: 34711288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management Strategies of Patients with Neuromyelitis Optica Spectrum Disorder During the COVID-19 Pandemic Era.
    Hamdy SM; Abdel-Naseer M; Shehata HS; Shalaby NM; Hassan A; Elmazny A; Shaker E; Nada MAF; Ahmed SM; Hegazy MI; Mourad HS; Abdelalim A; Magdy R; Othman AS; Mekkawy DA; Kishk NA
    Ther Clin Risk Manag; 2020; 16():759-767. PubMed ID: 32884277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of the mitigating effect of colon-specific bioreversible codrugs of mycophenolic acid and aminosugars in an experimental colitis model in Wistar rats.
    Chopade SS; Dhaneshwar SS
    World J Gastroenterol; 2018 Mar; 24(10):1093-1106. PubMed ID: 29563754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vitro Influence of Mycophenolic Acid on Selected Parameters of Stimulated Peripheral Canine Lymphocytes.
    Guzera M; Szulc-Dąbrowska L; Cywińska A; Archer J; Winnicka A
    PLoS One; 2016; 11(5):e0154429. PubMed ID: 27138877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The compelling case for therapeutic drug monitoring of mycophenolate mofetil therapy.
    Filler G; Alvarez-Elías AC; McIntyre C; Medeiros M
    Pediatr Nephrol; 2017 Jan; 32(1):21-29. PubMed ID: 26921212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time dependent neuroprotection of mycophenolate mofetil: effects on temporal dynamics in glial proliferation, apoptosis, and scar formation.
    Ebrahimi F; Koch M; Pieroh P; Ghadban C; Hobusch C; Bechmann I; Dehghani F
    J Neuroinflammation; 2012 May; 9():89. PubMed ID: 22569136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity.
    Ritter ML; Pirofski L
    Transpl Infect Dis; 2009 Aug; 11(4):290-7. PubMed ID: 19497072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy with mycophenolate mofetil for refractory acute and chronic GVHD.
    Furlong T; Martin P; Flowers ME; Carnevale-Schianca F; Yatscoff R; Chauncey T; Appelbaum FR; Deeg HJ; Doney K; Witherspoon R; Storer B; Sullivan KM; Storb R; Nash RA
    Bone Marrow Transplant; 2009 Dec; 44(11):739-48. PubMed ID: 19377515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted inhibition of glucuronidation markedly improves drug efficacy in mice - a model.
    Basu NK; Kole L; Basu M; McDonagh AF; Owens IS
    Biochem Biophys Res Commun; 2007 Aug; 360(1):7-13. PubMed ID: 17586469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil.
    O'Neill BP; Vernino S; Dogan A; Giannini C
    Neuro Oncol; 2007 Jul; 9(3):364-9. PubMed ID: 17522336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining the role of mycophenolate mofetil in the treatment of proliferative lupus nephritis.
    Lenz O; Fornoni A; Contreras G
    Drugs; 2005; 65(17):2429-36. PubMed ID: 16296869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphological findings in lymphatic tissues of sheep following oral application of the immunosuppressive mycotoxin mycophenolic acid.
    Baum B; Mohr A; Pfaffl M; Bauer J; Hewicker-Trautwein M
    Mycopathologia; 2005 Sep; 160(2):167-75. PubMed ID: 16170614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic allograft nephropathy and mycophenolate mofetil introduction in paediatric renal recipients.
    Kerecuk L; Taylor J; Clark G
    Pediatr Nephrol; 2005 Nov; 20(11):1630-5. PubMed ID: 16133052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. To what extent does the understanding of pharmacokinetics of mycophenolate mofetil influence its prescription.
    Filler G; Lepage N
    Pediatr Nephrol; 2004 Sep; 19(9):962-5. PubMed ID: 15257455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two lessons from the interface of genetics and medicine.
    Allison AC
    Genetics; 2004 Apr; 166(4):1591-9. PubMed ID: 15126382
    [No Abstract]   [Full Text] [Related]  

  • 20. Mycophenolate mofetil inhibits the development of Coxsackie B3-virus-induced myocarditis in mice.
    Padalko E; Verbeken E; Matthys P; Aerts JL; De Clercq E; Neyts J
    BMC Microbiol; 2003 Dec; 3():25. PubMed ID: 14687413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.